nach oben

Erschienen in:

21.01.2020 | Original Article

Enhanced glucose metabolism mediated by CD147 contributes to immunosuppression in hepatocellular carcinoma

verfasst von: Xiaofeng Li, Yufan Zhang, Wenchao Ma, Qiang Fu, Jianjing Liu, Guotao Yin, Peihe Chen, Dong Dai, Wei Chen, Lisha Qi, Xiaozhou Yu, Wengui Xu

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

From a metabolic perspective, cancer may be considered as a metabolic disease characterized by reprogrammed glycolytic metabolism. The aim of the present study was to investigate CD147-mediated glucose metabolic regulation in hepatocellular carcinoma (HCC) and its contribution to altered immune responses in the tumor microenvironment. Several HCC cell lines and corresponding nude mice xenografts models differing in CD147 expressions were established to directly investigate the role of CD147 in the reprogramming of glucose metabolism, and to determine the underlying molecular mechanisms. Immunohistochemistry (IHC) analyses and flow cytometry were used to identify the relationship between reprogrammed glycolysis and immunosuppression in HCC. Upregulated CD147 expressions were found to be associated with enhanced expressions of GLUT1, MCT1 in HCC tumorous tissues. CD147 promoted the glycolytic metabolism in HCC cell lines in vitro via the PI3K/Akt/mTOR signaling pathway. A positive correlation existed between a profile of immunosuppressive lymphocytes infiltration and CD147 expression in HCC tissues. Accumulation of FOXP3-expressing regulatory T cells was induced under a stimulation with lactate in vitro. In conclusion, CD147 promoted glycolytic metabolism in HCC via the PI3K/Akt/mTOR signaling pathway, and was related to immunosuppression in HCC.

Nur mit Berechtigung zugänglich

Lafaro KJ, Demirjian AN, Pawlik TM (2015) Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am 24:1–17CrossRef

Sangro B, Gomez-Martin C, de la Mata M et al (2013) A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 59:81–88CrossRef

Liu X, Qin S (2019) Immune checkpoint inhibitors in hepatocellular carcinoma: opportunities and challenges. Oncologist 24:S3–S10PubMedPubMedCentral

Floudas CS, Brar G, Greten TF (2019) Immunotherapy: current status and future perspectives. Dig Dis Sci 64:1030–1040CrossRef

Li X, Peng J, Pang Y et al (2015) Identification of a FOXP3(+)CD3(+)CD56(+) population with immunosuppressive function in cancer tissues of human hepatocellular carcinoma. Sci Rep 5:14757CrossRef

Speiser DE, Ho PC, Verdeil G (2016) Regulatory circuits of T cell function in cancer. Nat Rev Immunol 16:599–611CrossRef

Renner K, Singer K, Koehl GE et al (2017) Metabolic Hallmarks of tumor and immune cells in the tumor microenvironment. Front Immunol 8:248CrossRef

Kroemer G, Pouyssegur J (2008) Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell 13:472–482CrossRef

Hsu PP, Sabatini DM (2008) Cancer cell metabolism: warburg and beyond. Cell 134:703–707CrossRef

10.

Villalba M, Rathore MG, Lopez-Royuela N, Krzywinska E, Garaude J, Allende-Vega N (2013) From tumor cell metabolism to tumor immune escape. Int J Biochem Cell Biol 45:106–113CrossRef

11.

Chang CH, Qiu J, O’Sullivan D et al (2015) Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162:1229–1241CrossRef

12.

MacIver NJ, Michalek RD, Rathmell JC (2013) Metabolic regulation of T lymphocytes. Annu Rev Immunol 31:259–283CrossRef

13.

Siska PJ, Rathmell JC (2015) T Cell metabolic fitness in anti-tumor immunity. Trends Immunol 36:257–264CrossRef

14.

Domblides C, Lartigue L, Faustin B (2019) Control of the antitumor immune response by cancer metabolism. Cells 8(pii):E104CrossRef

15.

Brand A, Singer K, Koehl GE et al (2016) LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK Cells. Cell Metab 24:657–671CrossRef

16.

Scott KE, Cleveland JL (2016) Lactate wreaks havoc on tumor-infiltrating T and NK cells. Cell Metab 24:649–650CrossRef

17.

Zhao E, Maj T, Kryczek I et al (2016) Cancer mediates effector T cell dysfunction by targeting micro RNAs and EZH2 via glycolysis restriction. Nat Immunol 17:95–103CrossRef

18.

Xin X, Zeng X, Gu H et al (2016) CD147/EMMPRIN overexpression and prognosis in cancer: a systematic review and meta-analysis. Sci Rep 6:32804CrossRef

19.

Peng F, Li H, You Q et al (2017) CD147 as a novel prognostic biomarker for hepatocellular carcinoma: a meta-analysis. Biomed Res Int 2017:5019367PubMedPubMedCentral

20.

Li X, Yu X, Dai D, Song X, Xu W (2016) The altered glucose metabolism in tumor and a tumor acidic microenvironment associated with extracellular matrix metalloproteinase inducer and monocarboxylate transporters. Oncotarget 7:23141–23155PubMedPubMedCentral

21.

Ke X, Fei F, Chen Y et al (2012) Hypoxia upregulates CD147 through a combined effect of HIF-1α and Sp1 to promote glycolysis and tumor progression in epithelial solid tumors. Carcinogenesis 33:1598–1607CrossRef

22.

Huang Q, Li J, Xing J et al (2014) CD147 promotes reprogramming of glucose metabolism and cell proliferation in HCC cells by inhibiting the p53-dependent signaling pathway. J Hepatol 61:859–866CrossRef

23.

Dai JY, Dou KF, Wang CH et al (2009) The interaction of HAb18G/CD147 with integrin alpha6beta1 and its implications for the invasion potential of human hepatoma cells. BMC Cancer 9:337CrossRef

24.

Zhao P, Zhang W, Tang J et al (2010) Annexin II promotes invasion and migration of human hepatocellular carcinoma cells in vitro via its interaction with HAb18G/CD147. Cancer Sci 101:387–395CrossRef

25.

Yeung SJ, Pan J, Lee MH (2008) Roles of p53, MYC and HIF-1 in regulating glycolysis—the seventh hallmark of cancer. Cell Mol Life Sci 65:3981–3999CrossRef

26.

Zheng YL, Li L, Jia YX et al (2019) LINC01554-mediated glucose metabolism reprogramming suppresses tumorigenicity in hepatocellular carcinoma via downregulating PKM2 expression and inhibiting Akt/mTOR signaling pathway. Theranostics 9:796–810CrossRef

27.

Li X, Fu Q, Zhu Y et al (2019) CD147-mediated glucose metabolic regulation contributes to the predictive role of 18 F-FDG PET/CT imaging for EGFR-TKI treatment sensitivity in NSCLC. Mol Carcinog 58:247–257CrossRef

28.

Gou X, Tang X, Kong DK et al (2016) CD147 is increased in HCC cells under starvation and reduces cell death through upregulating p-mTOR in vitro. Apoptosis 21:110–119CrossRef

29.

Ganapathy-Kanniappan S (2017) Linking tumor glycolysis and immune evasion in cancer: emerging concepts and therapeutic opportunities. Biochim Biophys Acta Rev Cancer 1868:212–220CrossRef

30.

Ganapathy-Kanniappan S (2017) Taming tumor glycolysis and potential implications for immunotherapy. Front Oncol 7:36PubMedPubMedCentral

31.

Cham CM, Driessens G, O’Keefe JP, Gajewski TF (2008) Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8⁺ T cells. Eur J Immunol 38:2438–2450CrossRef

32.

San-Millán I, Brooks GA (2017) Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg Effect. Carcinogenesis 38:119–133PubMed

33.

Hirschhaeuser F, Sattler UG, Mueller-Klieser W (2011) Lactate: a metabolic key player in cancer. Cancer Res 71:6921–6925CrossRef

34.

Romero-Garcia S, Moreno-Altamirano MM, Prado-Garcia H, Sánchez-García FJ (2016) Lactate contribution to the tumor microenvironment: mechanisms, effects on immune cells and therapeutic relevance. Front Immunol 7:52CrossRef

35.

Feng J, Yang H, Zhang Y et al (2017) Tumor cell-derived lactate induces TAZ dependent upregulation of PD-L1 through GPR81 in human lung cancer cells. Oncogene 36:5829–5839CrossRef

36.

Caronni N, Simoncello F, Stafetta F et al (2018) Downregulation of membrane trafficking proteins and lactate conditioning determine loss of dendritic cell function in lung cancer. Cancer Res 78:1685–1699CrossRef

37.

Harmon C, Robinson MW, Hand F et al (2019) Lactate-mediated acidification of tumor microenvironment induces apoptosis of liver-resident NK cells in colorectal liver metastasis. Cancer Immunol Res 7:335–346CrossRef

38.

Long Y, Gao Z, Hu X et al (2018) Downregulation of MCT4 for lactate exchange promotes the cytotoxicity of NK cells in breast carcinoma. Cancer Med 7:4690–4700CrossRef

39.

Fischer K, Hoffmann P, Voelkl S et al (2007) Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109:3812–3819CrossRef

40.

Angelin A, Gil-de-Gómez L, Dahiya S et al (2017) FOXP3 reprograms T cell metabolism to function in low-glucose, high-lactate environments. Cell Metab 25:1282–1293CrossRef

Titel: Enhanced glucose metabolism mediated by CD147 contributes to immunosuppression in hepatocellular carcinoma
verfasst von: Xiaofeng Li
Yufan Zhang
Wenchao Ma
Qiang Fu
Jianjing Liu
Guotao Yin
Peihe Chen
Dong Dai
Wei Chen
Lisha Qi
Xiaozhou Yu
Wengui Xu
Publikationsdatum: 21.01.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 4/2020
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-019-02457-y

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Enhanced glucose metabolism mediated by CD147 contributes to immunosuppression in hepatocellular carcinoma

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

International Regensburg Center for Interventional Immunology (RCI) symposium on “Synthetic immunology and environment-adapted redirection of T cells”, 17–18 July, 2019, Regensburg, Germany

Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model

Digital pathology-aided assessment of tumor-infiltrating T lymphocytes in advanced stage, HPV-negative head and neck tumors

First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors

The expression and prognostic impact of proinflammatory cytokines and their associations with carcinogens in oropharyngeal squamous cell carcinoma

Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie